Figure 2
Figure 2. CYBB gene expression in U937 cells. Wild-type U937 cells (A) and U937 cells transfected with empty vector (B) show that the NF-κB inhibitors dexamethasone and gliotoxin decreased the levels of CYBB gene expression in myelomonocytic cells induced to differentiate by IFN-γ and TNF-α (P < .05 in all situations; n = 8, Mann-Whitney test). (C) Marked down-regulation of CYBB transcript levels in a U937 subclone transfected with IκB S32A/S36A, not affected by treatment with exogenous inhibitors. In all panels: lanes 1, 3, and 5, undifferentiated U937 cells; lanes 2, 4, and 6, U937 cells induced to differentiate by IFN-γ and TNF-α; lanes 1 and 2, no inhibitor; lanes 3 and 4, dexamethasone (1 μmol/L); lanes 5 and 6, gliotoxin (10 μmol/L).

CYBB gene expression in U937 cells. Wild-type U937 cells (A) and U937 cells transfected with empty vector (B) show that the NF-κB inhibitors dexamethasone and gliotoxin decreased the levels of CYBB gene expression in myelomonocytic cells induced to differentiate by IFN-γ and TNF-α (P < .05 in all situations; n = 8, Mann-Whitney test). (C) Marked down-regulation of CYBB transcript levels in a U937 subclone transfected with IκB S32A/S36A, not affected by treatment with exogenous inhibitors. In all panels: lanes 1, 3, and 5, undifferentiated U937 cells; lanes 2, 4, and 6, U937 cells induced to differentiate by IFN-γ and TNF-α; lanes 1 and 2, no inhibitor; lanes 3 and 4, dexamethasone (1 μmol/L); lanes 5 and 6, gliotoxin (10 μmol/L).

Close Modal

or Create an Account

Close Modal
Close Modal